Oculis Holding AG
OCS•NASDAQ•Healthcare•Biotechnology

About Oculis Holding

Oculis Holding AG, a clinical-stage biopharmaceutical company, develops drug candidates to treat ophthalmic diseases in Switzerland, Iceland, and internationally. The company’s lead product candidate is OCS-01, a topical dexamethasone optireach formulation, which is in Phase 3 clinical trials for the treatment of diabetic macular edema; OCS-02, a topical biologic candidate that is in Phase 2b clinical trials for the treatment for dry eye disease; and OCS-05, a disease modifying neuroprotective agent for neurological damage with indications for glaucoma, dry age-related macular degeneration and diabetic retinopathy, and acute optic neuritis. Oculis Holding AG was formerly known as Oculis SA and changed its name to Oculis Holding AG in March 2023. The company was founded in 2017 and is based in Zug, Switzerland.

Company Information

SectorHealthcare
IndustryBiotechnology
CEORiad Sherif
Founded2003
Employees49
CountrySwitzerland
Fiscal YearJanuary - December

Stock Details

ExchangeNASDAQ (NASDAQ)
CurrencyCHF - CHF
TypeStock

Contact Information

Websiteoculis.com
Phone41 41 711 3960
Address
Bahnhofstrasse 20 Zug, 6300 Switzerland

Corporate Identifiers

CIK0001953530
ISINCH1242303498
SIC2834

Leadership Team & Key Executives

Dr. Riad Sherif M.B.A., M.D.
Chief Executive Officer and Director
Sylvia Cheung
Chief Financial Officer
Gudrun Bachmann Ph.D.
Chief Technology Officer
Dr. Ramin Tadayoni M.D., Ph.D.
Chief Scientific Officer
Daniel S. Char J.D.
Chief Legal Officer
Virginia R. Dean
Chief Human Resources Officer
Páll Ragnar Jóhannesson
Chief Business Officer
Rebecca Weil Ph.D.
Chief Commercial Officer
Dr. Snehal Shah Pharm.D.
President of Research and Development
Dr. Sharon Klier M.D., M.P.H.
Chief Development Officer